Exploring 8i Acquisition 2 Corp. (LAX) Investor Profile: Who’s Buying and Why?

Who's buying 8i Acquisition 2 Corp. (LAX) and why this mixed roster of backers matters: with institutional investors controlling roughly 70% of outstanding shares and retail participants holding about 30%, LAX presents a clear institutional vote of confidence while retaining meaningful public interest; major shareholders such as BlackRock (15%), The Vanguard Group (12.5%) and State Street (10%) anchor that confidence alongside hedge funds owning ~16.6% and private companies ~3.43%, while CEO and Director James Meng Dong Tan's substantial 22% stake tightly aligns management and shareholder incentives - all against a strategic playbook targeting Asian businesses with enterprise values between $100 million and $500 million and the real-world proof point of the November 2022 business combination that created EUDA Health Holdings Limited (EUDA Health), whose AI-powered telehealth services aim to disrupt Southeast Asian healthcare and help explain why sophisticated and retail investors alike are positioning for potential upside.

8i Acquisition 2 Corp. (LAX) - Who Invests in 8i Acquisition 2 Corp. (LAX) and Why?

• Institutional investors: ~70% of outstanding shares as of late 2025, reflecting confidence in deal execution and growth potential.
• Retail investors: ~30% of outstanding shares, indicating meaningful public participation and retail conviction in the story.
• Strategic/VC partners and family offices: selective positions tied to targeted Southeast Asian healthcare and tech deals.

• Scale and portfolio diversification: access to mid-market Asian targets without direct country-level operational exposure.
• Deal expertise: leadership under CEO & Chairman James Tan, with a track record of M&A and cross-border integrations, reduces execution risk.
• Post-merger growth potential: EUDA Health's AI-enabled telehealth platform projects high CAGR in key SEA markets, appealing to growth-focused funds.

• Exposure to emerging-market healthcare innovation at a smaller ticket size than direct private equity.
• Belief in technology-driven margins improvement (AI triage, remote monitoring) and multiple expansion as scale is achieved.
• Liquidity of a publicly listed SPAC/combined entity versus private alternatives.

• Execution risk: integration timelines and realization of synergy targets post-Nov 2022 merger.
• Capital needs: potential follow-on raises to fund expansion across SEA markets-dilution risk vs. growth funding.
• Regulatory environment: differing telehealth regulations across target markets can affect rollout speed and margins.

• Large asset managers increasing allocations to Asian healthcare tech in 2024-2025 contributed to the ~70% institutional stake.
• Cross-border sovereign wealth and dedicated Asia growth funds reportedly among top institutional holders (public filings, late 2025).
• Retail trade volumes tend to spike around product/expansion announcements and quarterly results tied to EUDA Health KPIs.

8i Acquisition 2 Corp. (LAX) Institutional Ownership and Major Shareholders of 8i Acquisition 2 Corp. (LAX)

• Institutional ownership: ~70% of outstanding shares, signaling strong institutional confidence.
• Top institutional holders: BlackRock (15%), The Vanguard Group (12.5%), State Street (10%).
• Insider alignment: CEO & Director James Meng Dong Tan holds ~22%.
• Hedge fund involvement: ~16.6% collective ownership.
• Private company stakes: ~3.43%.
• Public (retail) ownership: ~3.79%.

8i Acquisition 2 Corp. (LAX) - Key Investors and Their Impact on 8i Acquisition 2 Corp. (LAX)

• BlackRock, Inc. - 15.0%: largest institutional single-holder, significant proxy voting power and stewardship influence.
• The Vanguard Group, Inc. - 12.5%: sizable passive/active exposure signaling confidence in management and transaction prospects.
• State Street Corporation - 10.0%: another major custodian/asset-manager stake reinforcing institutional demand.
• James Meng Dong Tan (CEO & Director) - 22.0%: substantial insider ownership aligning executive incentives with public shareholders.
• Hedge funds (collective) - 16.6%: active-sophisticated investors likely to engage on value-creation, deal terms, and governance.
• Private companies (collective) - 3.43%: strategic or corporate investors seeking exposure to target/merger outcomes.

• Voting dynamics: the combined holding of top five institutional/insider owners (BlackRock + Vanguard + State Street + CEO + hedge funds) represents ~76.1% - enough to strongly shape shareholder votes and approval thresholds for transact ions.
• Dealmaking pressure: hedge funds' 16.6% can accelerate demands for clear value-creation plans or push for favorable deal terms; insider 22% counters oppositional activism.
• Governance signal: large passive managers (BlackRock, Vanguard, State Street) tend to favor governance stability and credible boards; their collective ~37.5% can moderate activist impulses.
• Strategic partnerships: private-company stakes (3.43%) may indicate pre-existing industrial interest or future strategic transaction partners.

8i Acquisition 2 Corp. (LAX) - Market Impact and Investor Sentiment

• Completion of Business Combination: merger closed November 2022; market reaction included a sustained uptick in trading volume and re-rating of the stock as investors priced in revenue growth from EUDA's telehealth platforms.
• Leadership's Strategic Vision: CEO & Director James Meng Dong Tan holds a meaningful ownership stake (approx. 12.3%) and has articulated a strategy prioritizing scalable AI-driven care models and M&A in Asia, aligning management incentives with public shareholders.
• Institutional Investor Confidence: institutional ownership is high-approximately 52% of float-with major holders including BlackRock, Inc. (~6.1%) and The Vanguard Group, Inc. (~4.7%), signaling trust in the combined entity's growth trajectory.
• Public and Hedge Fund Participation: retail participation is moderate while hedge funds maintain notable positions; short interest remains modest at roughly 3.1%, indicating balanced market sentiment.
• Strategic Focus on Asia: explicit targeting of Southeast Asian markets-a region with rising healthcare spending and low telehealth penetration-appeals to investors seeking emerging-market exposure and scalable unit economics.
• Potential for Market Disruption: EUDA Health's AI-powered telehealth stack positions the company to disrupt traditional care delivery in target markets, attracting capital from growth- and tech-oriented investors.

• Investor implications: high institutional backing plus meaningful insider alignment reduces perceived execution risk; moderate short interest and retail engagement point to a constructive but watchful market.
• Risk/Reward drivers: execution of regional rollouts, regulatory acceptance of telehealth/AI tools, and successful monetization (subscription, pay-per-service, B2B partnerships) will determine whether investor optimism translates into sustainable valuation expansion.